Product Name: ACTL7A Antibody
Species Reactivity: Human
Tested Applications: WB
Applications: For WB starting dilution is: 1:1000
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 49 kDa
Immunogen: This ACTL7A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 41-67 amino acids from the N-terminal region of human ACTL7A.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 27208-80-6
Product: Polydatin
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Actin-like protein 7A, Actin-like-7-alpha, ACTL7A
Accession NO.: Q9Y615
Protein Ino: 27923725
Official Symbol: ACTL7A
Geneid: 10881
Background: ACTL7A is a member of a familyof actin-related proteins (ARPs) which share significant amino acidsequence identity to conventional actins. Both actins and ARPs havean actin fold, which is an ATP-binding cleft, as a common feature.The ARPs are involved in diverse cellular processes, includingvesicular transport, spindle orientation, nuclear migration andchromatin remodeling. ACTL7A (ACTL7A), and related gene, ACTL7B,are intronless, and are located approximately 4 kb apart in ahead-to-head orientation within the familial dysautonomia candidateregion on 9q31. Based on mutational analysis of the ACTL7A gene inpatients with this disorder, it was concluded that it is unlikelyto be involved in the pathogenesis of dysautonomia. The ACTL7A geneis expressed in a wide variety of adult tissues, however, its exactfunction is not known.
PubMed ID:http://aac.asm.org/content/52/3/1144.abstract
